Tolerance development in cow’s milk–allergic infants receiving amino acid–based formula: A randomized controlled trial
Формирование толерантности у младенцев с аллергией на белок коровьего молока, получающих смесь на основе аминокислот: рандомизированное контролируемое исследование
2021-07-02
SCID: 54.1/xb4n456s
Discuss with AI
IgE-mediated food allergyamino acid-based formulacow's milk allergydouble-blind food challengesynbiotics
Figures from the paper
Abstract (AI)
BACKGROUND: Tolerance development is an important clinical outcome for infants with cow's milk allergy. OBJECTIVE: This multicenter, prospective, randomized, double-blind, controlled clinical study (NTR3725) evaluated tolerance development to cow's milk (CM) and safety of an amino acid-based formula (AAF) including synbiotics (AAF-S) comprising prebiotic oligosaccharides (oligofructose, inulin) and probiotic Bifidobacterium breve M-16V in infants with confirmed IgE-mediated CM allergy. METHODS: Subjects aged ≤13 months with IgE-mediated CM allergy were randomized to receive AAF-S (n = 80) or AAF (n = 89) for 12 months. Stratification was based on CM skin prick test wheal size and study site. After 12 and 24 months, CM tolerance was evaluated by double-blind, placebo-controlled food challenge. A logistic regression model used the all-subjects randomized data set. RESULTS: At baseline, mean ± SD age was 9.36 ± 2.53 months. At 12 and 24 months, respectively, 49% and 62% of subjects were CM tolerant (AAF-S 45% and 64%; AAF 52% and 59%), and not differ significantly between groups. During the 12-month intervention, the number of subjects reporting at least 1 adverse event did not significantly differ between groups; however, fewer subjects required hospitalization due to serious adverse events categorized as infections in the AAF-S versus AAF group (9% vs 20%; P = .036). CONCLUSIONS: After 12 and 24 months, CM tolerance was not different between groups and was in line with natural outgrowth. Results suggest that during the intervention, fewer subjects receiving AAF-S required hospitalization due to infections.
Key Findings
1
A multicenter randomized double-blind trial compared amino acid-based formula with synbiotics (AAF-S) versus standard AAF in IgE-mediated cow’s milk-allergic infants.
2
Cow’s milk tolerance was achieved by 49% of infants after 12 months and 62% after 24 months, with no significant difference between AAF-S and AAF.
3
Overall adverse-event rates did not differ significantly, but infection-related hospitalization was lower with AAF-S than AAF (9% vs 20%; P = .036).
4
Tolerance development after both interventions was consistent with the expected natural outgrowth of cow’s milk allergy.
5
Tolerance rates were 45% versus 52% at 12 months and 64% versus 59% at 24 months for AAF-S and AAF, respectively.
Research Object
Infants with confirmed IgE-mediated cow’s milk allergy receiving amino acid–based formula with or without synbiotics
Research Subject
Development of cow’s milk tolerance and safety outcomes, including infection-related hospitalization, during formula intervention
Publication Details
Publication Date
2021-07-02
Journal
Publisher
ISSN
Cited by
48
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest